NCT06988150 Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
| NCT ID | NCT06988150 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cedars-Sinai Medical Center |
| Condition | Pancreatic Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-04-14 |
| Primary Completion | 2028-10-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-04-14 with a primary completion date of 2028-10-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.
Eligibility Criteria
Inclusion Criteria: * Men, Women, and all genders * Individuals 18 years old or older are included. * Patients of the study investigators and team members * Diagnosis of pancreatic ductal adenocarcinoma * All subjects must consent to this study * Clinically diagnosed weight loss Exclusion Criteria: * Minors * Pregnant Women * Any records flagged "break the glass" or "research opt out." * Patients who have received treatment for SIBO in the past 3 months
Contact & Investigator
Andrew E. Hendifar, M.D., M.P.H.
PRINCIPAL INVESTIGATOR
Cedars-Sinai Medical Center
Frequently Asked Questions
Who can join the NCT06988150 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06988150 currently recruiting?
Yes, NCT06988150 is actively recruiting participants. Contact the research team at GroupCancerTrialInformation@cshs.org for enrollment information.
Where is the NCT06988150 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06988150 clinical trial?
NCT06988150 is sponsored by Cedars-Sinai Medical Center. The principal investigator is Andrew E. Hendifar, M.D., M.P.H. at Cedars-Sinai Medical Center. The trial plans to enroll 100 participants.